In a recent study published in Nature,1 Kwok et al.identified tumor-wide antigens that derived from tumor-specific splicing events,known as neojunctions(NJs)(Fig.1a).The study identified two distinct neopeptide-encodi...In a recent study published in Nature,1 Kwok et al.identified tumor-wide antigens that derived from tumor-specific splicing events,known as neojunctions(NJs)(Fig.1a).The study identified two distinct neopeptide-encoding NJs(NEJs)that were spatially and temporally conserved in glioblastoma(GBM)patients and induced an HLA-dependent T cell response.The discovery of these NEJs,as well as the pipeline used for their identification,harbors significant potential for the development of tumor vaccines and adoptive cell therapies that might be effective across various cancer entities.展开更多
文摘In a recent study published in Nature,1 Kwok et al.identified tumor-wide antigens that derived from tumor-specific splicing events,known as neojunctions(NJs)(Fig.1a).The study identified two distinct neopeptide-encoding NJs(NEJs)that were spatially and temporally conserved in glioblastoma(GBM)patients and induced an HLA-dependent T cell response.The discovery of these NEJs,as well as the pipeline used for their identification,harbors significant potential for the development of tumor vaccines and adoptive cell therapies that might be effective across various cancer entities.
